183 related articles for article (PubMed ID: 9920537)
1. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Olson WH; Lippman JS; Robisch DM
Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
3. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
Redmond GP; Olson WH; Lippman JS; Kafrissen ME; Jones TM; Jorizzo JL
Obstet Gynecol; 1997 Apr; 89(4):615-22. PubMed ID: 9083323
[TBL] [Abstract][Full Text] [Related]
4. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
7. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study.
Sator PG; Schmidt JB; Hönigsmann H
Dermatology; 2003; 206(3):241-8. PubMed ID: 12673082
[TBL] [Abstract][Full Text] [Related]
9. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence.
Redmond G; Godwin AJ; Olson W; Lippman JS
Contraception; 1999 Aug; 60(2):81-5. PubMed ID: 10592854
[TBL] [Abstract][Full Text] [Related]
10. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
12. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
[TBL] [Abstract][Full Text] [Related]
14. The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
Carmina E; Godwin AJ; Stanczyk FZ; Lippman JS; Lobo RA
J Endocrinol Invest; 2002 Oct; 25(9):765-8. PubMed ID: 12398233
[TBL] [Abstract][Full Text] [Related]
15. Treating acne with oral contraceptives: use of lower doses.
Huber J; Walch K
Contraception; 2006 Jan; 73(1):23-9. PubMed ID: 16371290
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
17. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
18. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
Koltun W; Maloney JM; Marr J; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
[TBL] [Abstract][Full Text] [Related]
19. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Hendrix CW; Jackson KA; Whitmore E; Guidos A; Kretzer R; Liss CM; Shah LP; Khoo KC; McLane J; Trapnell CB
Clin Pharmacol Ther; 2004 May; 75(5):464-75. PubMed ID: 15116059
[TBL] [Abstract][Full Text] [Related]
20. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
